Aflibercept (DrugBank: Aflibercept)
2 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 90 | 網膜色素変性症 | 2 |
| 166 | 弾性線維性仮性黄色腫 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02661711 (ClinicalTrials.gov) | March 2016 | 13/1/2016 | Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study | Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP) | Macular Oedema;Retinitis Pigmentosa | Drug: Aflibercept | Moorfields Eye Hospital NHS Foundation Trust | Bayer | Active, not recruiting | 16 Years | N/A | Both | 30 | Phase 2 | United Kingdom |
| 2 | EUCTR2015-003723-65-GB (EUCTR) | 12/01/2016 | 06/01/2016 | Prospective non-randomised pilot study looking at the safety and efficacy of a drug called Eylea for patients with an eye condition called Retinitis Pigmentosa, that also have swelling at the back of the eye | Aflibercept (Eylea®) for macular oedema associated with underlying Retinitis Pigmentosa (AMOUR) - AMOUR | Retinitis Pigmentosa associated Cystoid Macular Oedema MedDRA version: 18.1;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Moorfields Eye Hospital | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02537054 (ClinicalTrials.gov) | September 2015 | 21/8/2015 | Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE) | Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE) | Pseudoxanthoma Elasticum | Drug: Aflibercept | University Hospital, Bonn | NULL | Completed | 18 Years | 65 Years | All | 15 | Phase 2 | Germany |
| 2 | EUCTR2014-005263-33-DE (EUCTR) | 29/04/2015 | 26/02/2015 | Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum | Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum - EyNeP | Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum MedDRA version: 20.0;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Trade Name: Eylea | Medizinische Fakultät der Universität Bonn | NULL | Not Recruiting | Female: yes Male: yes | 15 | Phase 2 | Germany |